The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
Latest news and blogs
News |
Russell Abberley, Amgen UK & Ireland, steps up as Acting ABPI President
News |
UK secures £400 million investment to boost clinical trials
Blog |
Understanding medicines access: a look at the severity modifier and its impact
Blog |
Latest Disclosure UK data: higher R&D spend, greater transparency and more partnership with the NHS
Accelerating transformation: How to develop effective NHS-industry partnerships
The NHS Confederation and the ABPI have created new guidance on how to create effective NHS-industry partnerships. It was created with the expertise of more than 30 NHS and industry leaders.
ABPI Manifesto for Investment, Health and Growth
This manifesto sets out the ABPI’s vision for how the UK can overtake its global competitors. Implementing these proposals will create a virtuous cycle, where investment in medicines and research accelerates future waves of innovation and attracts an increased UK share of global R&D.
NHS Industry Case Studies Library
Partnerships between the NHS and the pharmaceutical industry benefit patients and the NHS. Visit the ABPI's library of case studies of successful partnerships.
ABPI partnerships case study library
ABPI has published an interactive Pharma Impact Map, demonstrating the value of the pharmaceutical industry in different regional areas of all the four nations of the UK, down to constituency level. Data is available on economic value, manufacturing sites, jobs, NHS/industry collaborations, and research.
Events
Online Workshop on SMC: How to prepare and submit to SMC | 09-10 September 2024
Making high quality, evidence-based submissions to SMC can mean the difference between successful or very limited access to NHS Scotland for medicines.
NICE/DSU/ABPI masterclass – Methods for the analysis of non-randomised, patient level data for the estimation of treatment effects
NICE and the ABPI invite you to the third event in the NICE/DSU/ABPI Masterclass Programme in 2024 – Methods for the analysis of non-randomised, patient level data for the estimation of treatment effects
ABPI Industry Summit - Building trust in a time of change
This year sees a whirlwind of change around the world, shaping politics, technology and science as well as the way we communicate and receive information. It has never been more challenging for our industry to build trust and enhance reputation and tell the story of our mission to improve lives and tackle health inequalities.
NICE/DSU/ABPI Masterclass: Methods for mapping health utilities for NICE
NICE and the ABPI invite you to the fourth and final event in the NICE/DSU/ABPI Masterclass Programme in 2024 – Methods for mapping health utilities for NICE
Key facts and figures for the pharmaceutical industry in the UK
£46.7bn
Turnover [6]
£9bn
investment in UK R&D (more than UKRI’s entire annual budget) [3]
£17.6bn
direct Gross Value Added (GVA) [1]
Key content hubs
The COP28 summit will bring parties together to accelerate action towards the goals of the Paris Agreement and the UN Framework Convention on Climate Change.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.